Document










UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C.  20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 7, 2019

OMNICELL, INC.
(Exact name of registrant as specified in its charter)

Delaware
 
000-33043
 
94-3166458
(State or other jurisdiction of
incorporation or organization)
 
(Commission File Number)
 
(IRS Employer Identification Number)

590 East Middlefield Road
Mountain View, CA 94043
(Address of principal executive offices, including zip code)

(650) 251-6100
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company o       
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o       



1



Item 2.02 Results of Operations and Financial Condition

On February 7, 2019, Omnicell, Inc. issued a press release announcing its financial results for the quarter and the year ended December 31, 2018. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. A slide presentation, dated February 7, 2019, is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The slide presentation provides information that may be referred to by the Company on its conference call with investors scheduled to occur on February 7, 2019 in connection with the Company’s release of results for the fourth quarter of fiscal 2018.

The information in this Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Number
 
Description of Document
99.1
 
99.2
 




2



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 
OMNICELL,  INC.
 
 
 
Dated: February 7, 2019
 
 
 
 
/s/ Peter J. Kuipers
 
 
Peter J. Kuipers,
 
 
Executive Vice President and Chief Financial Officer
                                                      
                                                                           





3
Exhibit


Exhibit 99.1

http://api.tenkwizard.com/cgi/image?quest=1&rid=23&ipage=12683215&doc=9

Contact:
 
 
Peter Kuipers
 
Omnicell, Inc.
Chief Financial Officer
 
590 East Middlefield Road
800-850-6664
 
Mountain View, CA 94043
Peter.Kuipers@Omnicell.com
 
 


Omnicell Reports Results for Fiscal Year and Fourth Quarter 2018

Record yearly GAAP revenues of $787.3 million
Record yearly Non-GAAP revenues of $787.3 million
2018 GAAP net income per diluted share of $0.93
Record 2018 Non-GAAP net income per diluted share of $2.09
Record ending product backlog of $478 million


MOUNTAIN VIEW, Calif. -- February 7, 2019 -- Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication and supply management solutions to healthcare systems, today announced results for its fiscal year and fourth quarter ended December 31, 2018

GAAP Results

GAAP revenues for the fourth quarter of 2018 were $211.8 million, up $15.4 million, or 7.8% from the fourth quarter of 2017. GAAP revenues for the year ended December 31, 2018 were $787.3 million, up $74.6 million, or 10.5% from the year ended December 31, 2017.

Fourth quarter 2018 GAAP net income as reported was $14.8 million, or $0.36 per diluted share. This compares to GAAP net income of $31.2 million, or $0.79 per diluted share, for the fourth quarter of 2017.

GAAP net income for the year ended December 31, 2018 was $37.7 million, or $0.93 per diluted share. GAAP net income was $30.5 million, or $0.79 per diluted share, for the year ended December 31, 2017.

Non-GAAP Results

Non-GAAP revenues for the fourth quarter of 2018 were $211.8 million, up $15.1 million, or 7.7% from the fourth quarter of 2017.  Non-GAAP revenues for the year ended December 31, 2018 were $787.3 million, up $73.3 million, or 10.3% from the year ended December 31, 2017.

Non-GAAP net income for the fourth quarter of 2018 was $29.1 million, or $0.70 per diluted share. This compares to non-GAAP net income of $21.5 million, or $0.55 per diluted share, for the fourth quarter of 2017

Non-GAAP net income for the year ended December 31, 2018 was $84.6 million, or $2.09 per diluted share.  This compares to non-GAAP net income of $54.6 million, or $1.41 per diluted share for the year ended December 31, 2017

Non-GAAP net income for each period excludes, when applicable, the effect of share-based compensation expense, amortization expense of acquired intangible assets, acquisition-related expenses, fair value adjustments related to business acquisitions,

1



restructuring and severance-related expenses, tax reform and restructuring income tax benefits, contingent gains, and amortization of debt issuance cost.
Total product bookings for the year ended December 31, 2018 were $716 million compared to total bookings of $568 million for the year ended December 31, 2017. Total product backlog for the year ended December 31, 2018 was $478 million compared to $345 million for the year ended December 31, 2017, or an increase of 39% year over year.

“With the launch of our Autonomous Pharmacy vision at ASHP Midyear, health system pharmacists are understanding and embracing the need for radical change in medication management,” said Randall A. Lipps, chairman, president, chief executive officer, and founder of Omnicell. “We continue to partner with our customers to drive this revolutionary, digital approach, which will help allow nurses and pharmacists to move away from manual workflows and operate at the top of their license.”

2018 Business Highlights:

During 2018, the Company continued its cadence of innovation and introduced new products and solutions to the market including:
the XR2 Automated Central Pharmacy System, a robotic solution that is a significant step towards fully automating central pharmacy operations in a variety of settings;
IVX Workflow, which operates on IVX Cloud, creating a significant technological advancement for sterile compounding workflow processes and enabling pharmacies to safely and efficiently compound and prepare IV doses; and
the Patient Engagement Platform, which introduces new medication adherence capabilities and expands the reach of these solutions to Payer networks;
During the year, the Company has experienced good momentum on new products and has received numerous contractual purchase commitments for multiple products in the Omnicell Platform;
For the year ended December 31, 2018, the Company’s product backlog was $478 million, an increase of 39% from one year ago;
For the year ended December 31, 2018, the Company reported record product bookings of $716 million, an increase of 26% from one year ago; and
In December 2018, the Company announced its vision for the Autonomous Pharmacy. Omnicell’s vision for the Autonomous Pharmacy integrates a comprehensive set of solutions across three key areas:  Automation solutions designed to digitize and streamline workflows; Intelligence that provides actionable insights to better understand medication usage and improve pharmacy supply chain management; and Work - expert services that serve as an extension of pharmacy operations to support improved efficiency, regulatory compliance, and patient outcomes.

2019 Guidance:

For the first quarter of 2019, the Company expects non-GAAP total revenues to be between $196 million and $202 million. The Company expects non-GAAP product revenues to be between $140 million and $145 million, and non-GAAP service revenues to be between $56 million and $57 million. The Company expects first quarter 2019 non-GAAP earnings to be between $0.38 and $0.43 per share.

For the year 2019, the Company expects product bookings to be between $745 million and $780 million.

For the same period, the Company expects non-GAAP total revenues to be between $880 million and $900 million. The Company expects non-GAAP product revenues to be between $652 million and $668 million, and non-GAAP service revenues to be between $228 million and $232 million. The Company expects 2019 non-GAAP earnings to be between $2.40 and $2.60 per share.


2



The table below summarizes Omnicell's 2019 guidance outlined above:

 
Q1'19
Total Year 2019
Product Bookings
Not provided
$745 million - $780 million
Non-GAAP Total Revenues
$196 million - $202 million
$880 million - $900 million
Non-GAAP Product Revenues
$140 million - $145 million
$652 million - $668 million
Non-GAAP Service Revenues
$56 million - $57 million
$228 million - $232 million
Non-GAAP EPS
$0.38 - $0.43
$2.40 - $2.60

Omnicell Conference Call Information

Omnicell will hold a conference call today, Thursday, February 7, 2019 at 1:30 p.m. PT to discuss fourth quarter financial results. The conference call can be monitored by dialing 1-800-696-5518 within the U.S. or 1-706-758-4883 for all other locations. The Conference ID # is 4073668. Internet users can access the conference call at http://ir.omnicell.com/communications/events-presentations. A replay of the call will be available today at approximately 4:30 p.m. PT and will be available until 11:59 p.m. PT on March 21, 2019. The replay access numbers are 1-855-859-2056 within the U.S. and 1-404-537-3406 for all other locations, Conference ID # is 4073668.
 

About Omnicell

Since 1992, Omnicell has been inspired to create safer and more efficient ways to manage medications across all care settings. Through our industry-leading medication management platform that spans the continuum of care, Omnicell is developing a vision for a fully automated infrastructure, powered by a cloud data platform that supports improved patient care, fewer errors, enhanced safety, and new opportunities for growth.

Omnicell’s vision for the Autonomous Pharmacy integrates a comprehensive set of solutions across three key areas: Automation solutions designed to digitize and streamline workflows; Intelligence that provides actionable insights to better understand medication usage and improve pharmacy supply chain management; and Work - expert services that serve as an extension of pharmacy operations to support improved efficiency, regulatory compliance, and patient outcomes.

Over 5,000 facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety. And more than 40,000 institutional and retail pharmacies across North America and the United Kingdom leverage Omnicell's innovative medication adherence solutions to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions.

For more information about Omnicell, Inc. please visit www.omnicell.com.

Omnicell and the Omnicell logo are registered trademarks of Omnicell, Inc. in the United States and other countries.

Forward-Looking Statements

To the extent any statements contained in this release deal with information that is not historical, these statements are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. As such, they are subject to the occurrence of many events outside Omnicell’s control and are subject to various risk factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such statements include, but are not limited to, Omnicell’s projected bookings, revenues and earnings per share; pipeline; new products and solutions yet to be generally available; and new sales opportunities. Risks that contribute to the uncertain nature of the forward-looking statements include (i) Omnicell's ability to take advantage of the growth opportunities in medication management across the spectrum of healthcare settings from hospital to home, (ii) Omnicell's ability to develop and commercialize new products, including the XR2 Automated Central Pharmacy System and the IVX Workflow semi-automated workflow solution, and enhance existing products, (iii) Omnicell's ability to deliver on our vision of the Autonomous Pharmacy, (iv) unfavorable general economic and market conditions, (v) risks to growth and acceptance of Omnicell's products and services, including competitive conversions, (vi) growth of the clinical automation and workflow automation market generally, (vii) potential of increasing competition, (viii) potential regulatory changes, (ix) Omnicell's ability to improve sales productivity to grow product bookings, and (x) Omnicell's ability to acquire companies, businesses, or technologies and successfully integrate such acquisitions. These and other risks and uncertainties are described more fully in

3



Omnicell’s most recent filings with the Securities and Exchange Commission (“SEC”). Prospective investors are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date on which they were made. Omnicell undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Use of Non-GAAP Financial Information

This press release contains financial measures that are not calculated in accordance with GAAP. Our management evaluates and makes operating decisions using various performance measures. In addition to Omnicell’s GAAP results, we also consider non-GAAP revenues, non-GAAP gross profit, non-GAAP operating expenses, non-GAAP net income, and non-GAAP net income per diluted share. Additionally, we calculate adjusted EBITDA (another non-GAAP measure) by means of adjustments to GAAP net income. These non-GAAP results should not be considered as an alternative to gross profit, operating expenses, net income, net income per diluted share, or any other performance measure derived in accordance with GAAP. We present these non-GAAP results because we consider them to be important supplemental measures of Omnicell’s performance.

Our non-GAAP revenues, non-GAAP gross profit, non-GAAP operating expenses, non-GAAP net income, and non-GAAP net income per diluted share are exclusive of certain items to facilitate management’s review of the comparability of Omnicell’s core operating results on a period to period basis because such items are not related to Omnicell’s ongoing core operating results as viewed by management. We define our “core operating results” as those revenues recorded in a particular period and the expenses incurred within that period that directly drive operating income in that period. Management uses these non-GAAP financial measures in making operating decisions because, in addition to meaningful supplemental information regarding operating performance, the measures give us a better understanding of how we should invest in research and development, fund infrastructure growth and evaluate the effectiveness of marketing strategies. In calculating the above non-GAAP results, management specifically adjusted for the following excluded items:

a) 
Share-based compensation expense. We excluded from our non-GAAP results the expense related to equity-based compensation plans as they represent expenses that do not require cash settlement from Omnicell.

b) 
Amortization of acquired intangible assets. We excluded from our non-GAAP results the intangible assets amortization expense resulting from our past acquisitions. These non-cash charges are not considered by management to reflect the core cash-generating performance of the business and therefore are excluded from our non-GAAP results.

c) 
Amortization of debt issuance cost. Debt issuance cost represents costs associated with the issuance of Term Loan and Revolving Line of Credit facilities. The cost includes underwriting fees, original issue discount, ticking fee, and legal fees. This non-cash expense is not considered by management to reflect the core cash-generating performance of the business and therefore is excluded from our non-GAAP results.

d) 
Acquisition accounting impact related to deferred revenues. In connection with recent acquisitions, business combination rules require us to account for the fair values of arrangements for which acceptance has not been obtained, and post installation support has not been provided in our purchase accounting. The non-GAAP adjustment to our revenues is intended to include the full amounts of such revenues. We believe the adjustment to these revenues is useful as a measure of the ongoing performance of our business.

e) 
Acquisition-related expenses. We excluded from the non-GAAP results the expenses which are related to recent acquisitions. These expenses are unrelated to our ongoing operations and we do not expect them to occur in the ordinary course of business. We believe that excluding these acquisition related expenses provides more meaningful comparisons of the financial results to our historical operations and forward looking guidance and the financial results of less acquisitive peer companies.

f)
Severance and other related expenses. We excluded from our non-GAAP results the expenses which are related to restructuring events. These expenses are unrelated to our ongoing operations and we do not expect them to occur in the ordinary course of business. We believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward looking guidance and the financial results of peer companies.

g)
Tax impact from restructuring activity. We excluded from our non-GAAP results the income tax impacts related to restructuring activity. These impacts are unrelated to our ongoing operations, and we do not expect them to occur in the ordinary course of business. We believe that excluding these impacts provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and the financial results of peer companies.


4



h)
Contingent gain. We excluded from our non-GAAP results the contingent gain related to a settlement agreement associated with the Ateb acquisition. This contingent gain is unrelated to our ongoing operations, and we do not expect it to occur in the ordinary course of business. We believe that excluding this contingent gain provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and the financial results of peer companies.

Management adjusts for the above items because management believes that, in general, these items possess one or more of the following characteristics: their magnitude and timing is largely outside of Omnicell’s control; they are unrelated to the ongoing operation of the business in the ordinary course; they are unusual and we do not expect them to occur in the ordinary course of business; or they are non-operational, or non-cash expenses involving stock compensation plans or other items.


We believe that the presentation of these non-GAAP financial measures is warranted for several reasons: 

a)
Such non-GAAP financial measures provide an additional analytical tool for understanding Omnicell’s financial performance by excluding the impact of items which may obscure trends in the core operating results of the business; 

b)
Since we have historically reported non-GAAP results to the investment community, we believe the inclusion of non-GAAP numbers provides consistency and enhances investors’ ability to compare our performance across financial reporting periods; 

c)
These non-GAAP financial measures are employed by Omnicell’s management in its own evaluation of performance and are utilized in financial and operational decision making processes, such as budget planning and forecasting; and 

d)
These non-GAAP financial measures facilitate comparisons to the operating results of other companies in our industry, which use similar financial measures to supplement their GAAP results, thus enhancing the perspective of investors who wish to utilize such comparisons in their analysis of our performance.

Set forth below are additional reasons why share-based compensation expense is excluded from our non-GAAP financial measures:

i) 
While share-based compensation calculated in accordance with ASC 718 constitutes an ongoing and recurring expense of Omnicell, it is not an expense that requires cash settlement by Omnicell. We therefore exclude these charges for purposes of evaluating core operating results. Thus, our non-GAAP measurements are presented exclusive of stock-based compensation expense to assist management and investors in evaluating our core operating results. 

ii)
We present ASC 718 share-based payment compensation expense in our reconciliation of non-GAAP financial measures on a pre-tax basis because the exact tax differences related to the timing and deductibility of share-based compensation, under ASC 718 are dependent upon the trading price of Omnicell’s common stock and the timing and exercise by employees of their stock options. As a result of these timing and market uncertainties the tax effect related to share-based compensation expense would be inconsistent in amount and frequency and is therefore excluded from our non-GAAP results. 

Our adjusted EBITDA calculation is defined as earnings before interest income and expense, taxes, depreciation and amortization, and non-cash expenses, including ASC 718 share-based compensation expense, as well as certain non-GAAP adjustments.

As stated above, we present non-GAAP financial measures because we consider them to be important supplemental measures of performance. However, non-GAAP financial measures have limitations as an analytical tool and should not be considered in isolation or as a substitute for Omnicell’s GAAP results. In the future, we expect to incur expenses similar to certain of the non-GAAP adjustments described above and expect to continue reporting non-GAAP financial measures excluding such items. Some of the limitations in relying on non-GAAP financial measures are: 

a)
Omnicell’s stock option and stock purchase plans are important components of incentive compensation arrangements and will be reflected as expenses in Omnicell’s GAAP results for the foreseeable future under ASC 718. 

b)
Other companies, including companies in Omnicell’s industry, may calculate non-GAAP financial measures differently than Omnicell, limiting their usefulness as a comparative measure. 

Pursuant to the requirements of SEC Regulation G, a detailed reconciliation between Omnicell’s non-GAAP and GAAP financial results is set forth in the financial tables at the end of this press release. Investors are advised to carefully review and consider this information strictly as a supplement to the GAAP results that are contained in this press release and in Omnicell’s SEC filings.


5



Our 2019 guidance for non-GAAP earnings per share, as well as certain projections to be discussed in the conference call noted above, exclude “certain items,” which include but are not limited to: unusual gains and losses; costs associated with future restructurings; acquisition-related expenses; and certain tax and litigation outcomes. We do not provide a reconciliation of non-GAAP earnings per share guidance to the comparable GAAP measure as these items are inherently uncertain and difficult to estimate, and cannot be predicted without unreasonable effort. We believe such a reconciliation would imply a degree of precision that could be confusing to investors. These items may also have a material impact on GAAP earnings per share in future periods.


6



Omnicell, Inc.
Condensed Consolidated Statements of Operations
(Unaudited, in thousands, except per share data)

 
Three Months Ended
 
December 31,
2018
 
December 31, 2017
 
 
As Adjusted (a)
 
As Reported
 
Change
Revenues:
 
 
 
 
 
 
 
Product revenues
$
154,591

 
$
144,367

 
$
144,120

 
$
247

Services and other revenues
57,159

 
52,004

 
53,824

 
(1,820
)
Total revenues
211,750

 
196,371

 
197,944

 
(1,573
)
Cost of revenues:
 
 
 
 
 
 
 
Cost of product revenues
82,718

 
79,791

 
79,791

 

Cost of services and other revenues
26,849

 
23,085

 
23,085

 

Total cost of revenues
109,567

 
102,876

 
102,876

 

Gross profit
102,183

 
93,495

 
95,068

 
(1,573
)
Operating expenses:
 
 
 
 
 
 
 
Research and development
16,989

 
15,894

 
15,894

 

Selling, general, and administrative (b)
66,264

 
61,400

 
63,494

 
(2,094
)
Total operating expenses
83,253

 
77,294

 
79,388

 
(2,094
)
Income from operations
18,930

 
16,201

 
15,680

 
521

Interest and other income (expense), net
(2,314
)
 
(1,641
)
 
(1,641
)
 

Income before provision for income taxes
16,616

 
14,560

 
14,039

 
521

Provision for (benefit from) income taxes
1,823

 
(16,665
)
 
(10,252
)
 
(6,413
)
Net income
$
14,793

 
$
31,225

 
$
24,291

 
$
6,934

Net income per share:
 
 
 
 
 
 
 
Basic
$
0.37

 
$
0.82

 
$
0.64

 
$
0.18

Diluted
$
0.36

 
$
0.79

 
$
0.62

 
$
0.17

Weighted average shares outstanding:
 
 
 
 
 
 
 
Basic
39,913

 
38,127

 
38,127

 
 
Diluted
41,465

 
39,482

 
39,482

 
 

(a) As adjusted for full retrospective adoption of Accounting Standards Codification ("ASC") 606, Revenue from Contracts with Customers. The adjustment also includes a $0.3 million reclassification from services and other revenues to product revenues to conform with current-period presentation.
(b) Three months ended December 31, 2018 includes certain out-of-period adjustments that are not material to any previously issued financial statements.


7



Omnicell, Inc.
Condensed Consolidated Statements of Operations
(Unaudited, in thousands, except per share data)

 
Year Ended
 
December 31, 2018 (a)
 
December 31, 2017
 
 
As Adjusted (b)
 
As Reported
 
Change
Revenues:
 
 
 
 
 
 
 
Product revenues
$
569,595

 
$
510,201

 
$
506,209

 
$
3,992

Services and other revenues
217,714

 
202,513

 
209,956

 
(7,443
)
Total revenues
787,309

 
712,714

 
716,165

 
(3,451
)
Cost of revenues:
 
 
 
 
 
 
 
Cost of product revenues
312,360

 
304,842

 
304,842

 

Cost of services and other revenues
102,619

 
89,235

 
89,235

 

Total cost of revenues
414,979

 
394,077

 
394,077

 

Gross profit
372,330

 
318,637

 
322,088

 
(3,451
)
Operating expenses:
 
 
 
 
 
 
 
Research and development
64,843

 
66,022

 
66,022

 

Selling, general, and administrative (c)
263,095

 
241,470

 
250,312

 
(8,842
)
Total operating expenses
327,938

 
307,492

 
316,334

 
(8,842
)
Income from operations
44,392

 
11,145

 
5,754

 
5,391

Interest and other income (expense), net
(8,776
)
 
(6,633
)
 
(6,633
)
 

Income (loss) before provision for income taxes
35,616

 
4,512

 
(879
)
 
5,391

Provision for (benefit from) income taxes
(2,113
)
 
(26,006
)
 
(21,484
)
 
(4,522
)
Net income
$
37,729

 
$
30,518

 
$
20,605

 
$
9,913

Net income per share:
 
 
 
 
 
 
 
Basic
$
0.96

 
$
0.81

 
$
0.55

 
$
0.26

Diluted
$
0.93

 
$
0.79

 
$
0.53

 
$
0.26

Weighted average shares outstanding:
 
 
 
 
 
 
 
Basic
39,242

 
37,483

 
37,483

 
 
Diluted
40,559

 
38,712

 
38,712

 
 

(a) 
Includes a $0.6 million reclassification from services and other revenues to product revenues during the quarter ended June 30, 2018 to conform with current-period presentation.
(b) 
As adjusted for full retrospective adoption of ASC 606. The adjustment also includes a $0.8 million reclassification from services and other revenues to product revenues to conform with current-period presentation.
(c) Twelve months ended December 31, 2018 includes certain out-of-period adjustments that are not material to any previously issued financial statements

8




Omnicell, Inc.
Condensed Consolidated Balance Sheets
(Unaudited, in thousands)
 
December 31, 2018
 
December 31, 2017
 
 
As Adjusted (a)
 
As Reported
 
Change
 
 
 
 
 
 
 
 
ASSETS
Current assets:
 

 
 
 
 
 
 
Cash and cash equivalents
$
67,192

 
$
32,424

 
$
32,424

 
$

Accounts receivable and unbilled, net
196,238

 
190,046

 
189,227

 
819

Inventories
100,868

 
96,137

 
96,137

 

Prepaid expenses
20,700

 
20,392

 
36,060

 
(15,668
)
Other current assets
12,136

 
13,273

 
13,273

 

Total current assets
397,134

 
352,272

 
367,121

 
(14,849
)
Property and equipment, net
51,500

 
42,595

 
42,595

 

Long-term investment in sales-type leases, net
17,082

 
15,435

 
15,435

 

Goodwill
335,887

 
337,751

 
337,751

 

Intangible assets, net
143,686

 
168,107

 
168,107

 

Long-term deferred tax assets
15,197

 
9,454

 
9,454

 

Prepaid commissions
46,143

 
41,432

 

 
41,432

Other long-term assets
74,613

 
49,316

 
39,841

 
9,475

Total assets
$
1,081,242

 
$
1,016,362

 
$
980,304

 
$
36,058

 
 
 
 
 
 
 
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
 

 
 
 
 
 
 
Accounts payable
$
38,038

 
$
48,290

 
$
48,290

 
$

Accrued compensation
41,660

 
27,241

 
27,241

 

Accrued liabilities
43,047

 
35,693

 
35,693

 

Long-term debt, current portion, net

 
15,208

 
15,208

 

Deferred revenues, net
81,835

 
78,774

 
86,104

 
(7,330
)
Total current liabilities
204,580

 
205,206

 
212,536

 
(7,330
)
Long-term, deferred revenues
10,582

 
10,623

 
17,244

 
(6,621
)
Long-term deferred tax liabilities
41,484

 
41,446

 
28,579

 
12,867

Other long-term liabilities
9,562

 
9,829

 
9,829

 

Long-term debt, net
135,417

 
194,917

 
194,917

 

Total liabilities
401,625

 
462,021

 
463,105

 
(1,084
)
Total stockholders’ equity
679,617

 
554,341

 
517,199

 
37,142

Total liabilities and stockholders’ equity
$
1,081,242

 
$
1,016,362

 
$
980,304

 
$
36,058

(a) 
As adjusted for full retrospective adoption of ASC 606.


9



Omnicell, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited, in thousands)
 
Year Ended December 31,
 
2018
 
2017 (a)
Operating Activities
 
 
 
Net income
$
37,729

 
$
30,518

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
Depreciation and amortization
51,350

 
51,511

Loss on disposal of fixed assets
133

 
512

Share-based compensation expense
28,885

 
21,857

Income tax benefits from employee stock plans

 
11

Deferred income taxes
(5,705
)
 
(31,365
)
Amortization of debt financing fees
2,292

 
1,590

Changes in operating assets and liabilities:
 
 
 
 Accounts receivable and unbilled receivables
(6,192
)
 
(40,598
)
 Inventories
(6,763
)
 
(26,840
)
 Prepaid expenses
(308
)
 
(4,920
)
 Other current assets
1,170

 
(2,074
)
 Investment in sales-type leases
(1,680
)
 
6,625

 Prepaid commissions
(4,711
)
 
(3,966
)
 Other long-term assets
(7,077
)
 
(1,373
)
 Accounts payable
(9,154
)
 
19,709

 Accrued compensation
14,419

 
519

 Accrued liabilities
8,223

 
4,383

 Deferred revenues
3,020

 
(2,334
)
 Other long-term liabilities
(1,665
)
 
1,069

Net cash provided by operating activities
103,966

 
24,834

Investing Activities
 
 
 
Purchases of intangible assets, intellectual property, and patents

 
(160
)
Software development for external use
(30,677
)
 
(15,040
)
Purchases of property and equipment
(23,697
)
 
(15,341
)
Business acquisitions, net of cash acquired

 
(4,446
)
Net cash used in investing activities
(54,374
)
 
(34,987
)
Financing Activities
 
 
 
Proceeds from debt, net

 
56,894

Repayment of debt and revolving credit facility
(77,000
)
 
(102,500
)
Payment for contingent consideration

 
(2,400
)
At the market offering, net of offering costs
39,567

 
13,900

Proceeds from issuances under stock-based compensation plans
30,611

 
30,121

Employees' taxes paid related to restricted stock units
(6,775
)
 
(5,892
)
Net cash used in financing activities
(13,597
)
 
(9,877
)
Effect of exchange rate changes on cash and cash equivalents
(1,227
)
 
(2,034
)
Net increase (decrease) in cash and cash equivalents
34,768

 
(22,064
)
Cash and cash equivalents at beginning of period
32,424

 
54,488

Cash and cash equivalents at end of period
$
67,192

 
$
32,424


(a) 
As adjusted for full retrospective adoption of ASC 606.

10



Omnicell, Inc.
Reconciliation of GAAP to Non-GAAP
(Unaudited, in thousands, except per share data and percentage)
 
 
 
 
 
 
Three Months Ended
 
Twelve Months Ended
 
 
 
 
 
 
December 31,
2018
 
December 31, 2017 (a)
 
December 31,
2018
 
December 31, 2017 (a)
 
 
 
 
 
 
 
 
 
 
 
 
 
Reconciliation of GAAP revenues to non-GAAP revenues:
 
 
 
 
 
GAAP revenues
 
$
211,750

 
$
196,371

 
$
787,309

 
$
712,714

 
Acquisition accounting impact related to deferred revenues

 
313

 

 
1,252

Non-GAAP revenues
$
211,750

 
$
196,684

 
$
787,309

 
$
713,966

 
 
 
 
 
 
 
 
 
 
 
 
 
Reconciliation of GAAP gross profit to non-GAAP gross profit:
 
 
 
 
 
GAAP gross profit
$
102,183

 
$
93,495

 
$
372,330

 
$
318,637

GAAP gross margin
48.3%
 
47.6%
 
47.3%
 
44.7%
 
Share-based compensation expense
1,289

 
834

 
4,635

 
3,562

 
Amortization of acquired intangibles
3,091

 
2,818

 
11,366

 
11,488

 
Acquisition accounting impact related to deferred revenue

 
313

 

 
1,252

 
Severance and other expenses (b)
186

 
234

 
186

 
2,001

Non-GAAP gross profit
$
106,749

 
$
97,694

 
$
388,517

 
$
336,940

Non-GAAP gross margin
50.4%
 
49.7%
 
49.3%
 
47.2%
 
 
 
 
 
 
 
 
 
 
 
 
 
Reconciliation of GAAP operating expenses to non-GAAP operating expenses:
 
 
 
 
GAAP operating expenses
$
83,253

 
$
77,294

 
$
327,938

 
$
307,492

GAAP operating expenses % to total revenues
 
39.3%
 
39.4%
 
41.7%
 
43.1%
 
Share-based compensation expense
(6,745
)
 
(4,708
)
 
(24,250
)
 
(18,295
)
 
Amortization of acquired intangibles
(2,937
)
 
(3,348
)
 
(12,330
)
 
(14,008
)
 
Acquisition-related expenses

 

 

 
(126
)
 
Severance and other expenses (b)
(1,157
)
 
(233
)
 
(4,337
)
 
(3,764
)
Non-GAAP operating expenses
$
72,414

 
$
69,005

 
$
287,021

 
$
271,299

Non-GAAP operating expenses % to total non-GAAP revenues
34.2%
 
35.1%
 
36.5%
 
38.0%
 
 
 
 
 
 
 
 
 
 
 
 
 
Reconciliation of GAAP income from operations to non-GAAP income from operations:
GAAP income from operations
 
$
18,930

 
$
16,201

 
$
44,392

 
$
11,145

GAAP operating income % to total revenues
 
8.9%
 
8.3%
 
5.6%
 
1.6%
 
Share-based compensation expense
8,034

 
5,542

 
28,885

 
21,857

 
Amortization of acquired intangibles
6,028

 
6,166

 
23,696

 
25,496

 
Acquisition accounting impact related to deferred revenue

 
313

 

 
1,252

 
Acquisition-related expenses

 

 

 
126

 
Severance and other expenses
1,343

 
467

 
4,523

 
5,765

Non-GAAP income from operations
$
34,335

 
$
28,689

 
$
101,496

 
$
65,641

Non-GAAP operating income % to total non-GAAP revenues
16.2%
 
14.6%
 
12.9%
 
9.2%

(a) 
As adjusted for full retrospective adoption of ASC 606.
(b) 
Other expenses include relocation charge of $578, restructuring rent expense of $510, integration consulting expense of $201, and depreciation adjustment related to purchase price allocation from acquisition of $1,013 for the year ended December 31, 2017.

11



 
 
 
 
 
 
Three Months Ended
 
Twelve Months Ended
 
 
 
 
 
 
December 31, 2018
 
December 31, 2017 (a)
 
December 31, 2018
 
December 31, 2017 (a)
Reconciliation of GAAP net income to non-GAAP net income:
 
 
 
 
 
GAAP net income
$
14,793

 
$
31,225

 
$
37,729

 
$
30,518

 
Tax reform benefit impact

 
(20,005
)
 

 
(20,005
)
 
Tax benefit for restructuring activity

 

 
(4,205
)
 

 
Share-based compensation expense
8,034

 
5,542

 
28,885

 
21,857

 
Amortization of acquired intangibles
6,028

 
6,166

 
23,696

 
25,496

 
Acquisition accounting impact related to deferred revenue

 
313

 

 
1,252

 
Acquisition related expenses
397

 
397

 
1,589

 
1,715

 
Severance and other expenses
1,519

 
467

 
5,227

 
5,765

 
Contingent gain

 

 
(2,456
)
 

 
Tax effect of the adjustments above (b)
(1,668
)
 
(2,570
)
 
(5,891
)
 
(11,980
)
Non-GAAP net income
$
29,103

 
$
21,535

 
$
84,574

 
$
54,618

 
 
 
 
 
 
 
 
 
 
 
 
 
Reconciliation of GAAP net income per share - diluted to non-GAAP net income per share - diluted:
 
 
Shares - diluted GAAP
41,465

 
39,482

 
40,559

 
38,712

 
 
 
 
 
 
 
 
 
 
 
 
 
Shares - diluted Non-GAAP
41,465

 
39,482

 
40,559

 
38,712

 
 
 
 
 
 
 
 
 
 
 
 
 
GAAP net income per share - diluted
$
0.36

 
$
0.79

 
$
0.93

 
$
0.79

 
Tax reform benefit impact

 
(0.50
)
 

 
(0.52
)
 
Tax benefit for restructuring activity

 

 
(0.10
)
 

 
Share-based compensation expense
0.18

 
0.14

 
0.72

 
0.56

 
Amortization of acquired intangibles
0.15

 
0.16

 
0.58

 
0.67

 
Acquisition accounting impact related to deferred revenue

 
0.01

 

 
0.03

 
Acquisition related expenses
0.01

 
0.01

 
0.04

 
0.04

 
Severance and other expenses
0.04

 
0.01

 
0.13

 
0.15

 
Contingent gain

 

 
(0.06
)
 

 
Tax effect of the adjustments above (b)
(0.04
)
 
(0.07
)
 
(0.15
)
 
(0.31
)
Non-GAAP net income per share - diluted
$
0.70

 
$
0.55

 
$
2.09

 
$
1.41

 
 
 
 
 
 
 
 
 
 
 
 
 
Reconciliation of GAAP net income to non-GAAP Adjusted EBITDA:
 
 
 
 
 
GAAP net income
$
14,793

 
$
31,225

 
$
37,729

 
$
30,518

 
Share-based compensation expense
8,034

 
5,542

 
28,885

 
21,857

 
Interest (income) and expense, net
907

 
1,202

 
5,855

 
6,072

 
Depreciation and amortization expense
13,860

 
12,969

 
51,350

 
51,511

 
Acquisition accounting impact related to deferred revenue

 
313

 

 
1,252

 
Acquisition related expenses
397

 
397

 
1,589

 
1,715

 
Severance and other expenses
1,519

 
213

 
5,227

 
4,752

 
Contingent gain

 

 
(2,456
)
 

 
Income tax expense (benefit)
1,823

 
(16,665
)
 
(2,113
)
 
(26,006
)
Non-GAAP Adjusted EBITDA (c)
$
41,333

 
$
35,196

 
$
126,066

 
$
91,671

(a) 
As adjusted for full retrospective adoption of ASC 606.
(b) 
Tax effects calculated for all adjustments except tax benefits and share-based compensation expense, using an estimated annual effective tax rate of 21% for fiscal year 2018 and 35% for fiscal year 2017.
(c) 
Defined as earnings before interest income and expense, taxes, depreciation and amortization, share-based compensation expense, as well as excluding certain non-GAAP adjustments.

12



Omnicell, Inc.
Segmented Information
(Unaudited, in thousands, except for percentages)

 
Three Months Ended December 31, 2018
 
Three Months Ended December 31, 2017
 
Automation and
Analytics
 
Medication
Adherence
 
Total
 
Automation and
Analytics (a)
 
Medication
Adherence
 
Total
Revenues
$
177,605

 
$
34,145

 
$
211,750

 
$
161,569

 
$
34,802

 
$
196,371

Cost of revenues
85,157

 
24,410

 
109,567

 
79,225

 
23,651

 
102,876

Gross profit
92,448

 
9,735


102,183


82,344


11,151


93,495

Gross margin %
52.1%
 
28.5%
 
48.3%
 
51.0%

32.0%

47.6%
 
 
 
 
 
 
 
 
 
 
 
 
Operating expenses
45,731

 
10,311

 
56,042

 
44,955

 
10,539

 
55,494

Income (loss) from segment operations
$
46,717

 
$
(576
)

$
46,141

 
$
37,389

 
$
612

 
$
38,001

Operating margin %
26.3%
 
(1.7)%
 
21.8%
 
23.1%
 
1.8%
 
19.4%
 
 
 
 
 
 
 
 
 
 
 
 
Corporate costs
 
 
 
 
27,211

 
 
 
 
 
21,800

Income from operations
 
 
 
 
$
18,930

 
 
 
 
 
$
16,201


a) 
As adjusted for full retrospective adoption of ASC 606.

13



Omnicell, Inc.
Segmented Information
(Unaudited, in thousands, except for percentages)


 
Year Ended December 31, 2018
 
Year Ended December 31, 2017
 
Automation and
Analytics
 
Medication
Adherence
 
Total
 
Automation and
Analytics (a)
 
Medication
Adherence
 
Total
Revenues
$
655,679

 
$
131,630

 
$
787,309

 
$
586,941

 
$
125,773

 
$
712,714

Cost of revenues
319,257

 
95,722

 
414,979

 
308,443

 
85,634

 
394,077

Gross profit
336,422

 
35,908

 
372,330

 
278,498

 
40,139

 
318,637

Gross margin %
51.3%
 
27.3%
 
47.3%
 
47.4%
 
31.9%
 
44.7%
 
 
 
 
 
 
 
 
 
 
 
 
Operating expenses
188,303

 
41,430

 
229,733

 
184,857

 
41,735

 
226,592

Income (loss) from segment operations
$
148,119

 
$
(5,522
)
 
$
142,597

 
$
93,641

 
$
(1,596
)
 
$
92,045

Operating margin %
22.6%
 
(4.2)%
 
18.1%
 
16.0%
 
(1.3)%
 
12.9%
 
 
 
 
 
 
 
 
 
 
 
 
Corporate costs
 
 
 
 
98,205

 
 
 
 
 
80,900

Income from operations
 
 
 
 
$
44,392

 
 
 
 
 
$
11,145


(a) 
As adjusted for full retrospective adoption of ASC 606.




14



Omnicell, Inc.
Segment Information - Non-GAAP Gross Profit and Non-GAAP Operating Margin
(Unaudited, in thousands, except for percentages)

 
Three Months Ended December 31, 2018
 
Automation and
Analytics
 
Medication
Adherence
 
Total
 
Amount
 
% of GAAP Revenue
 
% of Non-GAAP Revenue
 
Amount
 
% of GAAP Revenue
 
% of Non-GAAP Revenue
 
Amount
 
% of GAAP Revenue
 
% of Non-GAAP Revenue
Revenues
$
177,605

 
 
 
 
 
$
34,145

 
 
 
 
 
$
211,750

 
 
 
 
Non-GAAP Revenues
$
177,605

 
 
 
 
 
$
34,145

 
 
 
 
 
$
211,750

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GAAP Gross profit
$
92,448

 
52.1
%
 
 
 
$
9,735

 
28.5
 %
 
 
 
$
102,183

 
48.3
 %
 
 
Share-based compensation expense
1,098

 
0.6
%
 
0.6
%
 
191

 
0.6
 %
 
0.6
%
 
1,289

 
0.6
 %
 
0.6
 %
Amortization expense of acquired intangible assets
2,603

 
1.5
%
 
1.5
%
 
488

 
1.4
 %
 
1.4
%
 
3,091

 
1.5
 %
 
1.5
 %
Severance and other expenses
3

 
%
 
%
 
183

 
0.5
 %
 
0.5
%
 
186

 
0.1
 %
 
0.1
 %
Non-GAAP Gross profit
$
96,152

 
 
 
54.1
%
 
$
10,597

 
 
 
31.0
%
 
$
106,749

 
 
 
50.4
 %
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GAAP Operating income
$
46,717

 
26.3
%
 
 
 
$
(576
)
 
(1.7
)%
 
 
 
$
46,141

 
21.8
 %
 
 
Share-based compensation expense
3,573

 
2.0
%
 
2.0
%
 
644

 
1.9
 %
 
1.9
%
 
4,217

 
2.0
 %
 
2.0
 %
Amortization expense of acquired intangible assets
4,438

 
2.5
%
 
2.5
%
 
1,590

 
4.7
 %
 
4.7
%
 
6,028

 
2.8
 %
 
2.8
 %
Severance and other expenses
330

 
0.2
%
 
0.2
%
 
213

 
0.6
 %
 
0.6
%
 
543

 
0.3
 %
 
0.3
 %
Non-GAAP Operating income
$
55,058

 
 
 
31.0
%
 
$
1,871

 
 
 
5.5
%
 
$
56,929

 
 
 
26.9
 %
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GAAP Corporate costs
 
 
 
 
 
 
 
 
 
 
 
 
$
27,211

 
12.9
 %
 
 
Share-based compensation expense
 
 
 
 
 
 
 
 
 
 
 
 
(3,817
)
 
(1.8
)%
 
(1.8
)%
Severance and other expenses
 
 
 
 
 
 
 
 
 
 
 
 
(800
)
 
(0.4
)%
 
(0.4
)%
Non-GAAP Corporate costs
 
 
 
 
 
 
 
 
 
 
 
 
$
22,594

 
 
 
10.7
 %
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Non-GAAP Income from operations
 
 
 
 
 
 
 
 
 
 
 
 
$
34,335

 
 
 
16.2
 %





15



Omnicell, Inc.
Segment Information - Non-GAAP Gross Profit and Non-GAAP Operating Margin
(Unaudited, in thousands, except for percentages)

 
Three Months Ended December 31, 2017
 
Automation and
Analytics
(a)
 
Medication
Adherence
 
Total
 
Amount
 
% of GAAP Revenue
 
% of Non-GAAP Revenue
 
Amount
 
% of GAAP Revenue
 
% of Non-GAAP Revenue
 
Amount
 
% of GAAP Revenue
 
% of Non-GAAP Revenue
Revenues
$
161,569

 
 
 
 
 
$
34,802

 
 
 
 
 
$
196,371

 
 
 
 
Acquisition accounting impact related to deferred revenue

 

 

 
313

 

 

 
313

 

 

Non-GAAP Revenues
$
161,569

 
 
 
 
 
$
35,115

 
 
 
 
 
$
196,684

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GAAP Gross profit
$
82,344

 
51.0
%
 

 
$
11,151

 
32.0
%
 

 
$
93,495

 
47.6
 %
 

Share-based compensation expense
704

 
0.4
%
 
0.4
%
 
130

 
0.4
%
 
0.4
%
 
834

 
0.4
 %
 
0.4
 %
Amortization expense of acquired intangible assets
2,251

 
1.4
%
 
1.4
%
 
567

 
1.6
%
 
1.6
%
 
2,818

 
1.4
 %
 
1.4
 %
Acquisition accounting impact related to deferred revenue

 
%
 
%
 
313

 
0.9
%
 
0.9
%
 
313

 
0.2
 %
 
0.2
 %
Severance and other expenses
234

 
0.1
%
 
0.1
%
 

 
%
 
%
 
234

 
0.1
 %
 
0.1
 %
Non-GAAP Gross profit
$
85,533

 

 
52.9
%
 
$
12,161

 

 
34.6
%
 
$
97,694

 

 
49.7
 %
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GAAP Operating income
$
37,389

 
23.1
%
 

 
$
612

 
1.8
%
 

 
$
38,001

 
19.4
 %
 

Share-based compensation expense
2,184

 
1.4
%
 
1.4
%
 
376

 
1.1
%
 
1.1
%
 
2,560

 
1.3
 %
 
1.3
 %
Amortization expense of acquired intangible assets
4,364

 
2.7
%
 
2.7
%
 
1,802

 
5.2
%
 
5.1
%
 
6,166

 
3.1
 %
 
3.1
 %
Acquisition accounting impact related to deferred revenue

 
%
 
%
 
313

 
0.9
%
 
0.9
%
 
313

 
0.2
 %
 
0.2
 %
Severance and other expenses
204

 
0.1
%
 
0.1
%
 

 
%
 
%
 
204

 
0.1
 %
 
0.1
 %
Non-GAAP Operating income
$
44,141

 

 
27.3
%
 
$
3,103

 

 
8.8
%
 
$
47,244

 

 
24.0
 %
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GAAP Corporate costs
 
 
 
 
 
 
 
 
 
 
 
 
$
21,800

 
11.1
 %
 

Share-based compensation expense
 
 
 
 
 
 
 
 
 
 
 
 
(2,982
)
 
(1.5
)%
 
(1.5
)%
Acquisition-related expenses
 
 
 
 
 
 
 
 
 
 
 
 
(263
)
 
(0.1
)%
 
(0.1
)%
Non-GAAP Corporate costs
 
 
 
 
 
 
 
 
 
 
 
 
$
18,555

 

 
9.4
 %
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Non-GAAP Income from operations
 
 
 
 
 
 
 
 
 
 
 
 
$
28,689

 

 
14.6
 %

(a) 
As adjusted for full retrospective adoption of ASC 606.

16
exhibit992slidepresentat
2018 Fourth Quarter and Full Year Earnings Call February 7, 2019 © 2019 Omnicell, Inc. Content is confidential and proprietary


 
3,000% Increase in Administrators since 1970 © 2019 Omnicell, Inc. Content is confidential and proprietary 1


 
76% Non-clinical Activities 7 25,000 1 4 errors / day 3 Errors annually in Pharmacy dispensing 250 Rx daily hospitals dispensing 5M doses 0.5% 1 6-10% 2 1.7%3 20-30% 4 30-35% 5 Non-IV Dispensing Mean Error Rate Dispensing Errors Prescriptions Med Related Errors in Central Pharmacy in IV Compounding in Outpatient Pharmacy Never Filled Readmission CENTRAL PHARMACY CLEAN ROOM MEDICATION ROOM SURGICAL SUITE OUTPATIENT PHARMACY HOME 1. Poon, China, Churchill, et al. 2. Flynn, Pearson & Barker. 3. Flynn, Barker, Carnahan 4. Brody J. 5. ASCP Ann Intern Med 2006; 145:426-434 Am J Health-Syst Pharm 1997; 54:904-12 Am J Pharm Assoc 2003: 43:191-200 New York Times, April 2017 The Consultant Pharmacist, October 2017 $450 Billion annual spend …6 with suboptimal outcomes 6. IQVIA Institute report (2018). Medicine Use & Spending in the U.S. 7. ASHP Survey (2015)AM J Health-Syst Pharm, September 2016 © 2019 Omnicell, Inc. Content is confidential and proprietary 2


 
Omnicell Products © 2019 Omnicell, Inc. Content is confidential and proprietary 3


 
Healthcare Market Trends & Omnicell Solutions Are Strongly Aligned Omnicell Solution Healthcare Trend Market Need Strength Health systems consolidation Integrated & automated 60% of top health systems are horizontally systems customers… broadest portfolio Pharmacy becoming More sophisticated ROI Clear innovation leader and more strategic based solutions strategic partner choice Provider – Payor vertical Increased need for Population Emerging broadest portfolio integration health solutions across continuum of care © 2019 Omnicell, Inc. Content is confidential and proprietary 4